{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:08:19Z","timestamp":1791821299377,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40264-024-01433-5","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T06:01:38Z","timestamp":1714802498000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Christopher A.","family":"Gravel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-4006","authenticated-orcid":false,"given":"Antonios","family":"Douros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"key":"1433_CR1","first-page":"1","volume-title":"Handbook of epidemiology","author":"E Garbe","year":"2022","unstructured":"Garbe E, Suissa S, Douros A. Pharmacoepidemiology. In: Ahrens W, Pigeot I, editors. Handbook of epidemiology. New York: Springer; 2022. p. 1\u201355."},{"key":"1433_CR2","doi-asserted-by":"publisher","unstructured":"Jones JK, Kingery E. History of pharmacovigilance. In: Mann's pharmacovigilance (Third edition) Andrews EB, Moore N, editors. West Sussex, Wiley Blackwell. 2014: p. 11\u201324. https:\/\/doi.org\/10.1002\/9781118-820186.","DOI":"10.1002\/9781118-820186"},{"issue":"4","key":"1433_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep."},{"key":"1433_CR4","unstructured":"Emanuel R, Ugo M, Francesco S, et al. Evolving roles of spontaneous reporting systems to assess and monitor drug safety. In: Charmy SK, Manan S, Rajvi Manthan P, editors. Pharmacovigilance. Rijeka: IntechOpen; 2018: Ch. 2."},{"issue":"9","key":"1433_CR5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.15802","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Douros A. Considerations on the use of different comparators in pharmacovigilance: a methodological review. Br J Clin Pharmacol. 2023;89(9):2671\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1433_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/pds.2022","volume":"19","author":"A Pariente","year":"2010","unstructured":"Pariente A, Didailler M, Avillach P, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19(11):1166\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1433_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1517\/14740338.6.4.451","volume":"6","author":"RP van Manen","year":"2007","unstructured":"van Manen RP, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf. 2007;6(4):451\u201364.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1433_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski AF, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469\u201390.","journal-title":"Drug Saf"},{"issue":"6","key":"1433_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/ije\/dyu149","volume":"43","author":"TL Lash","year":"2014","unstructured":"Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. Int J Epidemiol. 2014;43(6):1969\u201385.","journal-title":"Int J Epidemiol"},{"key":"1433_CR10","unstructured":"US Food and Drug Association Adverse Event Reporting System (AERS). https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 29 Apr 2024."},{"issue":"2","key":"1433_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"6","key":"1433_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jama.293.6.690","volume":"293","author":"GW Albers","year":"2005","unstructured":"Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690\u20138.","journal-title":"JAMA"},{"issue":"12","key":"1433_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"1433_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"1433_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/heartjnl-2016-310586","volume":"103","author":"A Alonso","year":"2017","unstructured":"Alonso A, MacLehose RF, Chen LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017;103(11):834\u20139.","journal-title":"Heart"},{"issue":"10","key":"1433_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jacc.2018.01.009","volume":"71","author":"A Douros","year":"2018","unstructured":"Douros A, Azoulay L, Yin H, Suissa S, Renoux C. Non-vitamin K antagonist oral anticoagulants and risk of serious liver injury. J Am Coll Cardiol. 2018;71(10):1105\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1433_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.14309\/ajg.0000000000000678","volume":"115","author":"J Zhao","year":"2020","unstructured":"Zhao J, Blais JE, Chui CSL, et al. Association between nonvitamin antagonist oral anticoagulants or warfarin and liver injury: a cohort study. Am J Gastroenterol. 2020;115(9):1513\u201324.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1433_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.12611","volume":"80","author":"E Raschi","year":"2015","unstructured":"Raschi E, Poluzzi E, Koci A, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80(2):285\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"1433_CR19","unstructured":"FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin#:~:text=Safety%20Announcement,(Farxiga%2C%20Xigduo%20XR. Accessed 29 Apr 2024."},{"issue":"24","key":"1433_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1433_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"1433_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"key":"1433_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1186","volume":"369","author":"B Pasternak","year":"2020","unstructured":"Pasternak B, Wintzell V, Melbye M, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ. 2020;369: m1186.","journal-title":"BMJ"},{"issue":"14","key":"1433_CR24","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1503\/cmaj.191283","volume":"192","author":"C Iskander","year":"2020","unstructured":"Iskander C, Cherney DZ, Clemens KK, et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ. 2020;192(14):E351\u201360.","journal-title":"CMAJ"},{"issue":"9","key":"1433_CR25","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/dom.14082","volume":"22","author":"A Fisher","year":"2020","unstructured":"Fisher A, Fralick M, Filion KB, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study. Diabetes Obes Metab. 2020;22(9):1648\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1433_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","volume":"9","author":"E Roux","year":"2005","unstructured":"Roux E, Thiessard F, Fourrier A, Begaud B, Tubert-Bitter P. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed. 2005;9(4):518\u201327.","journal-title":"IEEE Trans Inf Technol Biomed"},{"key":"1433_CR27","doi-asserted-by":"publisher","unstructured":"Farrell PJ GC, Krewski, D. Statistical methods for signal detection in spontaneous reporting databases. In: The encyclopedia of biopharmaceutical statistics-Four Volume Set (4th ed.). Chow SC ed. New\nYork, Chapman and Hall\/CRC. 2018: p. 2068\u201383. https:\/\/doi.org\/10.1201\/9781351110273.","DOI":"10.1201\/9781351110273"},{"issue":"7","key":"1433_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00228-020-02877-1","volume":"76","author":"D Mattison","year":"2020","unstructured":"Mattison D, Gravel C, Krewski D, Azoulay L, Hicks B, Douros A. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. Eur J Clin Pharmacol. 2020;76(7):1045\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"21","key":"1433_CR29","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Noren","year":"2006","unstructured":"Noren GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740\u201357.","journal-title":"Stat Med"},{"issue":"8","key":"1433_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/aje\/kwac035","volume":"191","author":"JJ Yland","year":"2022","unstructured":"Yland JJ, Wesselink AK, Lash TL, Fox MP. Misconceptions about the direction of bias from nondifferential misclassification. Am J Epidemiol. 2022;191(8):1485\u201395.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1433_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble JM. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2023;89(2):431\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1433_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743\u20139.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"1433_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014;37(11):971\u201380.","journal-title":"Drug Saf"},{"issue":"3","key":"1433_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","volume":"56","author":"R Neha","year":"2021","unstructured":"Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of notoriety bias in FDA Adverse Event Reporting System database and its impact on signal strength. Hosp Pharm. 2021;56(3):152\u20138.","journal-title":"Hosp Pharm"},{"issue":"6","key":"1433_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/pds.5217","volume":"30","author":"M Dorks","year":"2021","unstructured":"Dorks M, Jobski K, Hoffmann F, Douros A. Global COVID-19 pandemic and reporting behavior: an analysis of the Food and Drug Administration adverse events reporting system. Pharmacoepidemiol Drug Saf. 2021;30(6):707\u201315.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1433_CR36","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1111\/bcp.15711","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Krewski D, Mattison DR, Momoli F, Douros A. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis. Br J Clin Pharmacol. 2023;89(8):2430\u201345.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1433_CR37","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J. Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep. 2023;13(1):18817.","journal-title":"Sci Rep"},{"issue":"5","key":"1433_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H, Zethelius B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol. 2014;70(5):627\u201335.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1433_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2042098616685010","volume":"8","author":"M Hauben","year":"2017","unstructured":"Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8(5):145\u201356.","journal-title":"Ther Adv Drug Saf."},{"key":"1433_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668765","volume":"12","author":"C Khouri","year":"2021","unstructured":"Khouri C, Nguyen T, Revol B, et al. Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances. Front Pharmacol. 2021;12: 668765.","journal-title":"Front Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01433-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01433-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01433-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:33:44Z","timestamp":1722227624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01433-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01433-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"10 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christopher A. Gravel, William Bai, and Antonios Douros have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable given the use of fully anonymized, publicly available data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable given the use of fully anonymized, publicly available data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable given the use of fully anonymized, publicly available data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The raw data are publicly available here:\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code can be requested from Christopher A. Gravel.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CAG conducted the analyses. WB created the figures and critically revised the manuscript. AD supervised the study. CAG and AD designed the study and drafted the manuscript together. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}